Gastric Cancer Study Reveals Promising Chloroform Fraction Treatment

Researchers at Universidad Cientifica del Sur have made a breakthrough in gastric cancer treatment by discovering a potential therapeutic agent in the chloroform fraction of Dracontium spruceanum bulb. This natural compound, further referred to as DSBCl, has shown remarkable efficacy in modulating cancer stem cells (CSCs) and inhibiting tumor growth. The study, published in Scientific Reports, aims to highlight the therapeutic potential of DSBCl in treating gastric cancer, the fourth most common cancer globally and a leading cause of cancer-related deaths in Peru.

Key Takeaways:

• The study highlights the importance of distinguishing cancerous cells from healthy cells in cancer treatment, as current synthetic treatments often fail to do so.
• The chloroform fraction of Dracontium spruceanum bulb (DSBCl) has shown significant cytotoxic effects on cancer stem cells (CSCs) from AGS and KATO III gastric cancer cell lines.
• DSBCl modulates CSC markers and genes associated with tumorigenesis, chemoresistance, and metastasis, including CD24, ID1, BCL2L2, ABCC2, NANOG, and OCT4.
• AGS CSCs treated with DSBCl showed reduced CD24 expression and downregulated expression of ID1, BCL2L2, ABCC2, NANOG, and OCT4, while upregulating KLF17, BAX, and KLF4.
• In KATO III CSCs, DSBCl increased ID1 and MYC but decreased BCL2L1 and BAX, suggesting DSBCl's potential in modulating critical markers and genes in gastric CSCs.
• The study's findings suggest that DSBCl may be a valuable therapeutic agent in gastric cancer treatment, highlighting its potential for addressing cancer stem cells.

Sources:

• "The chloroform fraction of Dracontium spruceanum modulates gene expression in gastric cancer stem cells" (Scientific Reports, 2025, 15(1): 1-14)
• Universidad Cientifica del Sur (institution)
• Consejo Nacional De Ciencia, TecnologiA E InnovacioN Tecnologica (funding organization)
• Nature Portfolio (publisher of Scientific Reports)